Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(60.0%)

Early Phase 1

1(20.0%)

Phase 2

1(20.0%)

5Total

N/A(3)

Early Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04635072Early Phase 1Completed

Stabilized Whole Rice Bran (SWRB) for Mild to Moderate Atopic Dermatitis

Role: lead

NCT04243746Not ApplicableCompleted

Time Restricted Feeding to Reduce Weight and Cardiometabolic Risk

Role: lead

NCT03402646Not ApplicableUnknown

Mobile Phone Reminders (and Photovoice) for Routine Immunization in Nigeria - The MOPING Study

Role: collaborator

NCT02845557Completed

Glucose Homeostasis and Incretin Effect T2DM in the Youth- a Study of the Malaysian Population

Role: lead

NCT01992133Not ApplicableCompleted

Effects of Vitamin D Supplementation on Glucose Metabolism in Women With Former Gestational Diabetes Mellitus

Role: lead

NCT01855984Phase 2Completed

Tocotrienols for School-going Children With ADHD

Role: lead

All 6 trials loaded